Life Sciences GCCs: India's Next Talent Battleground
India's life sciences GCCs are evolving from cost centres into strategic innovation hubs, with 23 of the top 50 global life-sciences companies now operating in the country. These centres are expanding beyond traditional support functions into drug discovery, clinical development, regulatory affairs, and AI-driven analytics. Major players like Novartis, AstraZeneca, and Bristol Myers Squibb are investing heavily, with Hyderabad emerging as a key R&D hub. The shift is driven by access to specialised talent and digital capabilities, moving away from labour arbitrage towards high-value expertise. This transformation is reshaping India's role in the global pharmaceutical value chain. Key signal: 23 of the world's top 50 life-sciences companies have established GCCs in India, with over 36 pharma-focused GCCs employing more than 17,000 professionals. For hiring leaders, this matters because for CHROs and GCC leaders, this signals a significant shift in talent demand: life sciences GCCs are now competing for the same AI, data science, and engineering talent as tech firms. The convergence of life sciences and technology means hiring strategies must target hybrid profiles—professionals who combine domain expertise with digital fluency. As these centres move up the value chain, the war for specialised talent will intensify, especially in Bengaluru and Hyderabad. Companies that fail to invest in upskilling and industry-academia partnerships will struggle to attract and retain the leadership depth required for strategic roles. Teksands view: The life sciences GCC story is a clear signal that India's talent market is no longer just about IT services. The demand for hybrid talent—scientific knowledge plus AI/ML skills—is exploding, and the usual tech hiring playbook won't cut it. For recruiters, this means looking beyond traditional pharma talent pools to tap into data scientists, AI engineers, and cybersecurity experts who can navigate regulatory complexity. The real opportunity lies in building multidisciplinary teams that can drive innovation, not just execute. If you're not already thinking about life sciences GCCs as a talent destination, you're missing the next big wave.
Key fact
23 of the world's top 50 life-sciences companies have established GCCs in India, with over 36 pharma-focused GCCs employing more than 17,000 professionals.
Why it matters
For CHROs and GCC leaders, this signals a significant shift in talent demand: life sciences GCCs are now competing for the same AI, data science, and engineering talent as tech firms. The convergence of life sciences and technology means hiring strategies must target hybrid profiles—professionals who combine domain expertise with digital fluency. As these centres move up the value chain, the war for specialised talent will intensify, especially in Bengaluru and Hyderabad. Companies that fail to invest in upskilling and industry-academia partnerships will struggle to attract and retain the leadership depth required for strategic roles.
The Teksands point of view
The life sciences GCC story is a clear signal that India's talent market is no longer just about IT services. The demand for hybrid talent—scientific knowledge plus AI/ML skills—is exploding, and the usual tech hiring playbook won't cut it. For recruiters, this means looking beyond traditional pharma talent pools to tap into data scientists, AI engineers, and cybersecurity experts who can navigate regulatory complexity. The real opportunity lies in building multidisciplinary teams that can drive innovation, not just execute. If you're not already thinking about life sciences GCCs as a talent destination, you're missing the next big wave.
Got a tech role that's refusing to close?
Send us the JD. We'll tell you whether the problem is talent supply, compensation, location, process - or the JD itself.
